Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART123 and Ruxolitinib in Relapsed or Refractory AML
NCT06768476Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Feb 2025
- Primary completion
- Mar 2045
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART123 in acute myeloid leukemia (AML) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Safety of CART123 cells in combination with ruxolitinib at 15 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
CART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06768476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768476.